85 results on '"Yoshioka, H."'
Search Results
2. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
3. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
4. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure
5. 1357P Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
6. 1267P Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
7. 1263P Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)
8. 1243MO A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914
9. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
10. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
11. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study
12. 405P Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
13. LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
14. Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
15. Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
16. A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
17. Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge
18. Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
19. A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY)
20. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
21. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study
22. 333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
23. 481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
24. 460P Phase I/II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL; TORG1424/OLCSG1402): results of the phase I part
25. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
26. KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC)
27. 465P - A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
28. 440P - Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge
29. 1368P - Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
30. 1339P - A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY)
31. The Relationship Between the Grade of Peripheral Neuropathy and the Skin Blood Perfusion in Chemotherapy-Induced Peripheral Neuropathy Patients, and the Effects of Compression Therapy
32. Amrubicin (Amr) Versus Docetaxel (Dtx) As Second- or Third-Line Treatment for Non-Small Cell Lung Cancer (Nsclc): a Randomized Phase III Trial
33. Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study
34. 1259P - Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
35. 1221P - KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC)
36. Biomarker Analysis of WJOG4107 (A Randomized Phase II Trial of Adjuvant Chemotherapy with S-1 vs CDDP + S-1 in NSCLC)
37. Continuation Maintenance Therapy with Pemetrexed(PEM) ± Bevacizumab(BEV) Following First Line Cisplatin/PEM ± BEV for NSCLC
38. Circulating Tumor Cells as a Prognostic Marker in Metastatic Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy
39. Prognostic Impact of Central Nervous System Metastases and T790M Status After Acquired Resistance to EGFR-TKI
40. A Phase II Study of Pemetrexed in Chemotherapy-Naive Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003
41. Lux-Lung 3: Afatinib Versus Cisplatin and Pemetrexed in Japanese Patients with Adenocarcinoma of the Lung Harboring an EGFR Mutation
42. Rebiopsy of Non-Small-Cell Lung Cancer Patients with Acquired Resistance to EGFR-TKI: Comparison Between T790M Mutation-Positive and -Negative Populations
43. Randomized Phase II Study of Adjuvant Chemotherapy with S-1 Versus CDDP + S-1 in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (WJOG4107)
44. Retrospective Efficacy and Safety Analysis of Erlotinib (E), Pemetrexed (P) and Docetaxel (D) in Previously Treated Non-Small-Cell Lung Cancer Patients (NSCLC) without EGFR Mutation
45. A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903
46. A Phase II Study of Pemetrexed in Chemotherapy-Naïve Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003
47. Nested Case Control Study of Proteomic Biomarkers for Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Treated With Erlotinib
48. A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion
49. 1518P - The Relationship Between the Grade of Peripheral Neuropathy and the Skin Blood Perfusion in Chemotherapy-Induced Peripheral Neuropathy Patients, and the Effects of Compression Therapy
50. 1300P - Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.